Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.42) by 64.29 percent. This is a 130 percent decrease over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $3.695 million which missed the analyst consensus estimate of $4.869 million by 24.11 percent. This is a 27.63 percent increase over sales of $2.895 million the same period last year.